Accredited E-Newsletter Series

The Treatment of R/R cHL in the Era of Checkpoint Inhibitors
The Treatment of R/R cHL in the Era of Checkpoint Inhibitors
CME, CPE
Catherine Diefenbach, MD
Release Date: November 28, 2018
Expiration Date: November 28, 2019
The treatment landscape for relapsed/refractory classical Hodgkin lymphoma (R/R cHL) is expanding thanks to the development of immunotherapies like checkpoint inhibitors. In this activity, Dr. Catherine Diefenbach summarizes current salvage treatment options for R/R cHL—including their benefits and risks—and discusses the efficacy and safety of immunotherapy in the management of this difficult-to-treat patient population.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Bristol-Myers Squibb, Merck and Co., Inc., and Seattle Genetics, Inc.
Begin, Earn CreditView Only, No Credit
 
Advanced-stage cHL: Rethinking Our Options in Frontline Therapy
Advanced-stage cHL: Rethinking Our Options in Frontline Therapy
CME, CPE
Jonathon B. Cohen, MD, MS
Release Date: October 17, 2018
Expiration Date: October 17, 2019
New strategies are emerging to improve the frontline treatment of patients with newly diagnosed advanced-stage classical Hodgkin lymphoma (cHL). In this interview, Dr. Jonathon Cohen discusses results from recent clinical trials that are making an impact on the frontline management of advanced-stage cHL. He also outlines how these advances will influence clinical practice and positively impact current standards of care for the disease.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Bristol-Myers Squibb, Merck & Co., Inc., and Seattle Genetics, Inc.
Begin, Earn CreditView Only, No Credit
 
Individualized Treatment Approaches in Patients with Newly Diagnosed Hodgkin Lymphoma
Individualized Treatment Approaches in Patients with Newly Diagnosed Hodgkin Lymphoma
CME, CPE
Alison J. Moskowitz, MD
Release Date: September 10, 2018
Expiration Date: September 10, 2019
The management of patients with newly diagnosed Hodgkin lymphoma (HL) continues to evolve as new therapies and treatment approaches are being investigated and introduced. This activity will review helpful, evidence-based strategies for individualizing therapy in the frontline setting by describing emerging treatment regimens for newly diagnosed HL and the latest clinical data regarding these options.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Bristol-Myers Squibb, Merck & Co., Inc., and Seattle Genetics, Inc.
Begin, Earn CreditView Only, No Credit
 

Managing HL would like to recognize and thank Bristol-Myers Squibb, Merck & Co., Inc., and Seattle Genetics for their educational support of ManagingHodgkinLymphoma.com in 2018.

©2018 MediCom Worldwide, Inc. All rights reserved